---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-285929"
form_type: "8-K"
ticker: null
cik: "0001796129"
company_name: "Vincerx Pharma, Inc."
filed_at: "2024-12-27T23:59:59+00:00"
generated_at: "2026-05-28T23:05:49.330736+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vincerx Pharma to merge with Oqory; Vincerx shareholders to own ~5%; CEO and CFO depart

## Summary
- Binding term sheet for reverse triangular merger with Oqory; Vincerx stockholders to receive 5% of combined company, minimum $13.66M equity value.
- Interim financing of $1.5M from Oqory-designated investors; ~$1M funded via registered direct offering of 2.8M shares and warrants for ~$0.9M gross proceeds.
- CEO Ahmed Hamdy stepped down, remains Chairman; CFO Alexander Seelenberger departed; Raquel Izumi becomes Acting CEO, Kevin Haas Acting CFO.
- Workforce reduction approved with estimated $2.4M in severance costs, expected to be paid in Q4 2024 and Q1 2025.
- Closing conditions include due diligence, regulatory approvals, stockholder votes, and a concurrent investment of at least $20M.

## SEC filing metadata
- accession: 0001193125-24-285929
- form_type: 8-K
- cik: 0001796129
- company_name: Vincerx Pharma, Inc.
- filed_at: 2024-12-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796129/000119312524285929/0001193125-24-285929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796129/000119312524285929/d875384d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-285929
- JSON: https://secwatch.observer/filing/0001193125-24-285929.json
- Plain text: https://secwatch.observer/filing/0001193125-24-285929.txt

## Key facts
- Restructurings & Charges
  Vincerx Pharma, Inc. announced a restructuring with charges of approximately $2.4 million (an additional workforce reduction).
  - Type: restructuring
  - Charge: approximately $2.4 million
  - Headcount: an additional workforce reduction
  source text: The Company’s Board of Directors (“Board”) approved additional streamlining and cost-control measures on December 20, 2024, including an additional workforce reduction, as the Company pursues due diligence and transaction-related work in connection with the Term Sheet. The Company estimates that it will incur approximately $2.4 million in costs primarily related to severance costs and related expenses
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796129/000119312524285929/0001193125-24-285929-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.